Mason, OH-based magnetocardiography developer Genetesis has received clearance from Health Canada to market its CardioFlux system.
CardioFlux is a zero-contact imaging system that assesses cardiac function by examining the tiny magnetic fields produced by the heart's regular electrical activity to identify electrophysiological signs of myocardial ischemia. CardioFlux requires 90 seconds of data acquisition and does not require any stress, injections, or radiation, the company noted.
Genetesis is working diligently to identify Canadian partners interested in early adoption and integration of MCG technologies into the current standard of care, the company said.
